Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.
from Forbes Real Time https://www.forbes.com/sites/arleneweintraub/2017/10/11/here-come-more-gene-therapies-and-more-pricing-debates/
via IFTTT
No comments:
Post a Comment